General Information of Drug (ID: DM4BQFW)

Drug Name
omega-conotoxin GVIA Drug Info
Synonyms
UNII-CA669FO97Q; CA669FO97Q; omega-Cgtx; omega Cgtx; omega-Cgtx gvia; Conus geographus toxin; omega-Ctx; omega Conus geographus toxin; toxin, omega-Conus geographus; omega-Conopeptide gvia; Snx 124; omega-Conotoxin G VIA (reduced); 92078-76-7; GTPL2535; LS-187069
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
16133838
ChEBI ID
CHEBI:90630
CAS Number
CAS 106375-28-4
TTD Drug ID
DM4BQFW

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Preclinical Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flunarizine DMZU5JP Migraine 8A80 Approved [3]
XEN007 DMNKV3O Migraine 8A80 Phase 1 [3]
TH-9229 DMG1MPD Reperfusion injury ND56.Z Terminated [4]
CPU-228 DMM8FUT Cardiac failure BD10-BD13 Investigative [5]
Alpha-eudesmol DMYSCQU Discovery agent N.A. Investigative [6]
Drug Name Drug ID Indication ICD 11 Highest Status REF
LOMERIZINE DME0TC8 Migraine 8A80 Approved [7]
Ziconotide DMSLJP4 Pain MG30-MG3Z Approved [8]
Hesperidin DMI5DW1 Vascular purpura 3B60 Approved [9]
Cilnidipine DM1975O High blood pressure BA00 Phase 3 [10]
Ralfinamide DMUNMY0 Neuropathic pain 8E43.0 Phase 3 [11]
CNV-2197944 DMLT7JV Pain MG30-MG3Z Phase 2 [12]
Ritanserin DM0X36Y Anxiety disorder 6B00-6B0Z Discontinued in Phase 3 [13]
CNSB-004 DMHAI0M Pain MG30-MG3Z Preclinical [14]
TH-9229 DMG1MPD Reperfusion injury ND56.Z Terminated [4]
PD-157667 DM61NFD N. A. N. A. Terminated [15]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated calcium channel alpha Cav2.1 (CACNA1A) TTX4QDJ CAC1A_HUMAN Blocker (channel blocker) [2]
Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) TT4FDG6 CAC1B_HUMAN Blocker (channel blocker) [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2535).
2 Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes. J Biol Chem. 2000 Nov 10;275(45):35335-44.
3 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008159)
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 532).
6 Alpha-eudesmol, a P/Q-type Ca(2+) channel blocker, inhibits neurogenic vasodilation and extravasation following electrical stimulation of trigeminal ganglion. Brain Res. 2000 Aug 4;873(1):94-101.
7 Synthesis and SAR of novel 2-arylthiazolidinones as selective analgesic N-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Feb 1;17(3):662-7.
8 Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84.
9 In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
10 N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002 May;20(5):993-1000.
11 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
12 Clinical pipeline report, company report or official report of Convergence Pharmaceuticals Ltd.
13 N,N-dialkyl-dipeptidylamines as novel N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Mar 22;9(6):907-12.
14 CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain. Pain Med. 2010 Feb;11(2):262-73.
15 Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.